SML2721

GSK8612

≥98% (HPLC)

• Synonym(e): 4-(((5-Bromo-2-((3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)amino)methyl)benzenesulfonamide, 4-((5-Bromo-2-(3-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-ylamino)pyrimidin-4-ylamino)methyl)benzenesulfonamide, GSK 8612, GSK-8612
• Empirische Formel (Hill-System): C₁₇H₁₇BrF₃N₇O₂S
• CAS-Nummer: 2361659-62-1
• Molekulargewicht: 520.33
• MDL-Nummer: MFCD32062739
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: white to beige
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C

Beschreibung

Biochem./physiol. Wirkung

GSK8612 is a potent and highly selective tank-binding kinase-1 (TBK1) inhibitor (pIC₅₀ = 6.8; pK_d = 8.0 vs pK_a = 6.2/STK17B, 6.0/IKKε, 6.1/LRRK2, 6.0/FLT4, 5.8/ULK3, 5.7/BMP2K, 5.7/CSNK2A1, 5.6/CSNK2A2, 5.6/FLT4, 5.5/PIK3CD, <5.5/more than 270 kinases). GSK8612 inhibits IFNβ secretion induced by dsDNA containing virus or STING ligand cGAMP (IC₅₀ = 1.25 & 0.5 μM, respectively; THP-1), as well as suppresses TLR3 ligand poly(I:C)-induced IRF3 Ser396 phosphorylation (IC₅₀ = 1 μM; Ramos) and IFNα release (IC₅₀ = 0.79 μM; human PBMCs), a IFN positive feedback response steming from IFNβ.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable